RBC Capital Upgrades Dynavax Technologies (DVAX) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- US stock futures gain ahead of July inflation data
- Oil prices rise after ship attacks, US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Dynavax (DVAX) Doubles Early on FDA Panel Backing
July 31, 2017 6:58 AM EDTDynavax (NASDAQ: DVAX) shares are trading up 105% in pre-open trade following FDA panel backing for HEPLISAV-B for hepatitis B.
... MoreJPMorgan Upgrades Dynavax Technologies (DVAX) to Overweight, Negatively Revises EPS Estimates
July 31, 2017 4:45 AM EDTJPMorgan upgraded Dynavax Technologies (NASDAQ: DVAX) from Neutral to Overweight with a price target of $27.00 (from $6.00).
Analyst Anupam Rama believes Heplisav has a high probability of a approval come August 10th PDUFA. Rama further comments about the under-appreciated SD-101 asset "we believe... More
